Evaluation and validation of a duck IgY antibody-based immunoassay for high-sensitivity C-reactive protein: avian antibody application in clinical diagnostics.

1. Kovalevskaya G, Birken S, Kakuma T, Ozaki N, Sauer M, Lindheim S, et al. Differential expression of human chorionic gonadotropin (hCG) glycosylation isoforms in failing and continuing pregnancies: preliminary characterization of the hyperglycosylated hCG epitope. J Endocrinol 2002;172:497–506. 2. Elliott MM, Kardana A, Lustbader JW, Cole LA. Carbohydrate and peptide structure of the and -subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine 1997;7: 15–32. 3. Frendo JL, Vidaud M, Guibourdenche J, Luton D, Muller F, Bellet D, et al. Defect of villous cytotrophoblast differentiation in syncytiotrophoblast in Down’s syndrome. J Clin Endocrinol Metab 2000;85:3700–7. 4. Massin N, Frendo JL, Guibourdenche J, Luton D, Giovangrandi Y, Muller F, et al. Defect of syncytiotrophoblast formation and human chorionic gonadotropin expression in Down’s syndrome. Placenta 2001;22(Suppl A):S93–7. 5. Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney MJ. Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: a new basis for gestational Down syndrome screening. Clin Chem 1999;45:2109–19. 6. Kovalevskaya G, Genbacev O, Fisher S, Caceres E, O’Connor J. Trophoblast origin of hCG isoforms: cytotrophoblasts are the primary source of choriocarcinoma-like hCG. Mol Cell Endocrinol 2002;194:147–55. 7. Birken S, Krichevsky A, O’Connor J, Schlatterer J, Cole L, Kardana A, et al. Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient. Endocrine 1999;10: 137–44. 8. Kovalevskaya G, Birken S, Kakuma T, O’Connor JF. Early pregnancy human chorionic gonadotropin (hCG) isoforms measured by an immunometric assay for choriocarcinoma-like hCG. J Endocrinol 1999;161:99–106. 9. Cole LA, Omrani A, Cermik D, Bahado-Singh RO, Mahoney MJ. Hyperglycosylated hCG, a potential alternative to hCG in Down syndrome screening. Prenat Diagn 1998;18:926–33. 10. Cole LA, Shahabi S, Oz UA, Rinne KM, Omrani A, Bahado-Singh RO, et al. Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCG. Prenat Diagn 1999;19:351–9. 11. Bahado-Singh R, Oz U, Shahabi S, Omrani A, Mahoney M, Cole L. Urine hyperglycosylated hCG plus ultrasound biometry for detection of Down syndrome in the second trimester in a high-risk population. Obstet Gynecol 2000;95:889–94. 12. Khanlian SA, Smith HO, Cole LA. Persistent low levels of hCG: a premalignant gestational trophoblastic disease. Am J Obstet Gynecol;in press. 13. Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology [Review]. Clin Chem 1991;37:625–36. 14. Weeks I, Beheshti I, McCapra F, Campbell AK, Woodhead JS. Acridinium esters as high-specific-activity labels in immunoassay. Clin Chem 1983;29: 1474–9. 15. O’Connor JF, Ellish N, Kakuma T, Schlatterer J, Kovalevskaya G. Differential urinary gonadotropin profiles in early pregnancy and early pregnancy loss. Prenat Diagn 1998;18:1232–40. 16. Butler SA, Khanlian SA, Cole LA. Detection of early pregnancy forms of human chorionic gonadotropin by home pregnancy test devices. Clin Chem 2001;47:2131–6.